Cagrilintide: Research overview, identity, and laboratory handling guide

8 min read · Research use only

Written and reviewed by BluGen Research Team · Editorial standards

Long-acting amylin/calcitonin receptor agonist analogue studied in vitro for amylin-receptor pathway research. ≥99% HPLC. Research use only. This guide covers identity, published research context, procurement checks, and storage — RUO only, no clinical claims.

What Cagrilintide is in published research

Cagrilintide is a long-acting amylin and calcitonin receptor agonist analogue characterised in published research for in vitro binding at AMY and CT receptor complexes. The peptide carries a fatty-acid acylation that extends half-life in research models; published literature commonly pairs cagrilintide with GLP-1 analogues to study combination amylin/incretin signaling in cell systems.

Each lot ships with ≥99% HPLC purity, MS identity verification covering both the backbone and acyl modification, and net peptide content on the CoA.

Hold lyophilized vials at -20 °C in original packaging away from light. Reconstitute in lab-grade slightly alkaline buffer; aliquot before freezing.

CoA + lot batch records available for procurement.

The material class "Amylin analogue (research)" helps procurement teams group Cagrilintide with related reference peptides during comparative studies.

Sequence and identity

Cagrilintide identity on the catalog: Common name: Cagrilintide (AM833); Class: Long-acting amylin analogue, acylated; Molecular weight: ~3,800 g/mol (lot-specific on CoA); Appearance: White lyophilized powder; Purity (HPLC): ≥ 99%; Solubility: Soluble in slightly alkaline lab buffers. Copy these into receiving and LIMS before reconstitution.

Mechanisms studied in published research

Mechanism-focused research on Cagrilintide is typically conducted in cell lines or biochemical preparations that express the relevant receptor or binding protein for its class.

Design controls that include scrambled-sequence or orthogonal-receptor negative controls when your protocol evaluates Cagrilintide pharmacology in vitro.

Report effect sizes with lot number and CoA reference so results can be reproduced if the same Cagrilintide SKU is reordered later.

Avoid extrapolating in vitro binding or signaling readouts to whole-organism outcomes; RUO materials are not qualified for clinical investigation.

Procurement and identity verification

Request the lot-specific CoA for Cagrilintide at receipt. Verify SKU, variant size if applicable, and identity mass before the lot enters general storage.

Compare HPLC purity to your internal minimum for the peptide family. File chromatogram excerpts when your QMS requires raw data.

Enter net peptide content from the CoA into inventory before calculating molarity for Cagrilintide working stocks.

Attach purchase order, packing list, and CoA in one audit folder per lot.

Storage and reconstitution

Store lyophilized Cagrilintide sealed at -20 °C protected from light unless the CoA states otherwise.

Reconstitute with bacteriostatic water or a buffer validated for your assay pH. Aliquot to limit freeze-thaw.

For oxidation-sensitive sequences in Cagrilintide, minimize open-vial time at room temperature during weighing.

See our lyophilized storage guide for institution-scale SOP examples and aliquot labeling conventions.

Comparative reference points

Researchers comparing Cagrilintide with adjacent catalog references often evaluate the following SKUs in parallel plates:

Use matched reconstitution buffers and stock concentrations when running comparative binding or signaling assays.

Document reviewers should cross-link this guide with the product certificate of analysis and internal receiving SOP.

When publishing methods, cite lot number, SKU, reconstitution buffer, and stock concentration so external labs can interpret your figures.

Institutional procurement may require RUO acknowledgment at checkout; store that acknowledgment beside batch records for audits.